Wullich Bernd, Taubert Helge, Goebell Peter J, Kuwert Torsten, Beck Michael, Schott Christian, Baur Andreas S, Eckstein Markus, Wach Sven
Klinik für Urologie und Kinderurologie, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 12, 91054, Erlangen, Deutschland.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Deutschland.
Urologie. 2023 Sep;62(9):879-888. doi: 10.1007/s00120-023-02151-z. Epub 2023 Aug 1.
Spectacular advances have been made in personalized medicine , which has rapidly revolutionized our traditional understanding of disease diagnosis and treatment. Molecular testing of tissue and liquid samples using next generation sequencing has developed into a key technology in this scenario. It can be used for both the determination of biomarkers for diagnostic, prognostic and predictive purposes, as well as the possible improvement of treatment outcome through the use of targeted therapies and the avoidance of therapies in the event of special resistance situations. In addition to drugs that have already been approved, which among other things intervene in cellular DNA repair, many new drugs have been developed and are in clinical testing. Furthermore, new possibilities in molecular imaging have dramatically expanded our understanding of tumor spread and created new approaches for targeted therapies.
个性化医疗取得了惊人的进展,迅速彻底改变了我们对疾病诊断和治疗的传统认识。在这种情况下,使用下一代测序技术对组织和液体样本进行分子检测已发展成为一项关键技术。它既可以用于确定用于诊断、预后和预测目的的生物标志物,也可以通过使用靶向治疗以及在出现特殊耐药情况时避免治疗来可能改善治疗结果。除了已经获批的、可干预细胞DNA修复等的药物外,许多新药也已研发出来并正在进行临床试验。此外,分子成像的新可能性极大地扩展了我们对肿瘤扩散的认识,并为靶向治疗创造了新方法。